Please amend the application as follows:

In the specification:

Replace Table 1 on page 15 with the amended Table below.

Table 1. Nucleotide sequence of primers used to generate promoter fragments

Primer No.	Restriction site	Promoter sequence	Position	Sequence 5'-3'
1582	HindIII (AAG CTT)	SEQ ID NO: 1	3440-3424	AAG CTT CTC GGC GCG CGG GCC CG (SEQ ID NO: 3)
1583	NheI (GCT AGC)	SEQ ID NO: 1	2341-2362	GCT AGC CAA GAG CTT CTG GAG CCG (SEQ ID NO: 4)
1584	NheI (GCT AGC)	SEQ ID NO: 1	720-741	GCT AGC TGT TAC ATG CAG AGC AAT C (SEQ ID NO: 5)
1585	HindIII (AAG CTT)	SEQ ID NO: 2	4439-4421	AAG CTT CCT ACG GCC CCC GCG (SEQ ID NO: 6)
1586	NheI (GCT AGC)	SEQ ID NO: 2	3321-3340	GCT AGC GCG CAC TGC AAT GCC CTC (SEQ ID NO: 7)

Replace Table 2 on pages 20 and 21 with the amended Table below.

Table 2. Oligonucleotide primer used in the mutagenesis experiments

Primer	**Primer Sequences**
1949 P R1b Cre Fwd	CGCCGCCCGT**TTG**GTCAGAGCCCCCT (SEQ ID NO: 8)
1950 P R1b Cre Rev	AGGGGGCTCTGAC**CAA**ACGGGCGGCG (SEQ ID NO: 9)
1951 P R1a GCI Fwd	CTCTCTTCCCCCC**TAA**CTGCCTTCCC (SEQ ID NO: 10)
1952 P R1a GCI Rev	GGGAAGGCAG**TTA**GGGGGGAAGAGAG (SEQ ID NO: 11)
1953 P R1a GCII Fwd	GGCGGTCCAG**TTA**GGGGCTGGGATCC (SEQ ID NO: 12)
1954 P R1a GCII Rev	GGATCCCAGCCCC**TAA**CTGGACCGCC (SEQ ID NO: 13)
2051 P R1a GCIII Fwd	CCTCTCCACCGCCC**TAA**CCACCGCGCTGTG (SEQ ID NO: 14)
2052 P R1a GCIII Rev	CACAGCGCGGTGG**TTA**GGGCGGTGGAGAGG (SEQ ID NO: 15)

2053 P R1b GCIVs Fwd	CCCCAGCTCCCGCCC**TAA**CCCCCACCCC (SEQ ID NO: 16)
2054 P R1b GCIVs Rev	GGGGTGGGGG**TTA**GGGCGGGAGCTGGGG (SEQ ID NO: 17)
2055 P R1b GCV Fwd	CGCTTCCCTCCCC**TAA**CCCTTCCTGCC (SEQ ID NO: 18)
2056 P R1b GCV Rev	GGCAGGAAGGG**TTA**GGGGAGGGAAGCG (SEQ ID NO: 19)
2057 P R1b GCVI Fwd	CCCTCCCCTCCCC**TAA**CCTCCGACTGT (SEQ ID NO: 20)
2058 P R1b GCVI Rev	ACAGTCGGAGG**TTA**GGGGAGGGGAGGG (SEQ ID NO: 21)
2059 P R1b GCVII Fwd	CTCCGCCCACCCC**TAA**CTCCTGGCAC (SEQ ID NO: 22)
2060 P R1b GCVII Rev	GTGCCAGGAG**TTA**GGGGTGGGCGGAG (SEQ ID NO: 23)
2146 P R1b GCIVd Fwd	CCCCAGCTCCC**TAA**C**TAA**CCCCCACCCC (SEQ ID NO: 24)
2147 P R1b GCIVd Rev	GGGGTGGGGG**TTA**G**TTA**GGGAGCTGGGG (SEQ ID NO: 25)

Replace the legend to Figure 6 running from page 25, line 24 through page 26, line 3 with the amended legend below.

Figure 6. Identification of nuclear factors binding to the Plb consensus CRE site using CREB/ATF super-shift antibodies.

Nuclear extracts (5µg) from ND7/23 cells were incubated with double-stranded ^{32}P-labeled oligonucleotides containing the Plb consensus CRE site (sense:5'-CGCCGCCCGTGACGTCAGAGCCCCCT-3' (SEQ ID NO: 26)). In lane 1, no antibody was added. In lane 2, a mouse monoclonal antibody (sc-270 Santa Cruz Biotechnology, Santa Cruz, CA) reactive with members of the ATF/CREB family such as ATF-1 p35, CREB-1 p43 and CREM-1 was pre-incubated at room temperature for 20 min before addition of ^{32}P-labeled probe. The specific complex between nuclear factors and the CRE is indicated by a star and the super-shifted complex is indicated by two stars.

Replace the present Sequence Listing with the revised one on 11 substitute sheets enclosed herewith.